How outcomes are defined in randomized controlled trials of acute kidney injury: a scoping review
Authors' conclusion
Outcome reporting is heterogeneous, highlighting the need for a standardized core outcome set.
Study context
- Population
- Randomized controlled trials (RCTs) (2014–2024) of adults or children with acute kidney injury (AKI) or at risk for AKI
- Participants
- 251 RCTs
- Comparison
- Prevention trials vs Therapeutic RCTs
- Prevention trialsn = 197
- Therapeutic RCTsn = 54
- Primary endpoint
- Outcomes reported in RCTs of AKI prevention and treatment (core area, core domain, specific domain, measurement method, timing)
Methodological detailsPRISMA-ScR guidance, COMET taxonomy
- PRISMA-ScR guidance
- COMET taxonomy
Primary result
As reported in the abstract
Outcome categories
- Prevention trials
- 197/251 (78.5%)
- Prevention: Physiological/Clinical Core Area
- 194/197, 98.5%
- Prevention: Renal outcomes Core Domain
- 186/197, 94%
- Prevention: renal function
- 162/197, 82%
- Prevention: renal damage
- 15/197, 7.5%
- Prevention: serum creatinine alone
- 130/162, 80%
- Prevention: serum creatinine combined with urine output
- 25/162, 15%
- Prevention: assessed at 48-72 h
- 65%
- Prevention: assessed at 7 days
- 22%
- Therapeutic RCTs
- 54/251, 21.5%
- Therapeutic: Physiological/Clinical Core Area
- 37/54, 69%
- Therapeutic: Mortality/Survival Core Area
- 14/54, 26%
- Therapeutic: renal outcomes
- 33/54, 61%
- Therapeutic: renal function
- 9/54, 17%
- Therapeutic: renal recovery
- 10/54, 19%
- Therapeutic: use of RRT
- 3/54, 6%
- Therapeutic: serum creatinine
- 16/54, 30%
- Therapeutic: mortality
- 14/54, 26%
- Therapeutic: Estimated glomerular filtration rate (eGFR)
- 3/54, 6%
Original publication
How outcomes are defined in randomized controlled trials of acute kidney injury: a scoping review. Intensive Care Med. Published 27 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →